The entry of GSK adjuvant recombinant new crown vaccine into phase 3 clinical trials was delayed due to insufficient immune response

On May 27, local time, GlaxoSmithKline (GSK) announced that it has launched a phase 3 clinical trial of the adjuvant recombinant COVID-19 candidate vaccine developed in cooperation with Sanofi (SNF), which is expected to be in the United States, Asia, and Africa.

10 days ago, GSK just announced the Phase 2 clinical study data of this COVID-19 vaccine candidate, evaluating the immunogenicity of the two doses of the vaccine in 722 healthy volunteers 18 years and older.

The primary endpoint of this newly launched Phase 3 clinical study is the effectiveness of two doses of vaccine to prevent symptomatic COVID-19, and the secondary endpoint is the effectiveness of preventing severe COVID-19 and asymptomatic infections.

In addition, GSK and SNF will also explore the possibility of this vaccine as a booster vaccine in the next few weeks, which may create a larger market for this vaccine.

According to GSK, the vaccine will be approved by the U.

It is worth noting that this vaccine of GSK and Sanofi encountered a major "crisis" in December 2020.

One day before GSK announced the initiation of Phase 3 clinical studies of the COVID-19 vaccine, the monoclonal antibody therapy sotrovimab jointly developed by the company and Vir Biotechnology has received FDA Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19 Adult and pediatric patients.

Note: The original text has been deleted

Reference materials:

[1]https://us.

[2] -us-fda/